


# Cell Line Development Solutions for Biomanufacturing

Break through to next level of productivity


- GenScript ProBio high-expressing cell line technology ecosystem
- Stable cell line development
- ADCC-enhanced cell line development
- Service solutions and technology licenses

# Introduction of GenScript ProBio Cell Line Business



**GenScript ProBio** has built up a high-expressing, robust and well-proven cell line technology ecosystem. It is consisted of our proprietary CHO cell lines, CHOK1-GenS & CHOK1-ADCC+, high-expression vectors, proprietary media systems and high-throughput and automated clone screening system.

To date, we have constructed more than 180 stable cell lines for IND filing using our cell line platform and process.



GenScript ProBio's cell line technology ecosystem

Statistics by Dec. 2023

# **ProCLD Cell Line Development**


#### Superior Productivity

- mAb titer: average 5.8 g/L, up to 11 g/L
- bsAb titer: average 4.8 g/L, up to 10 g/L
- Recombinant protein titer: average 4.2 g/L, up to 14.5 g/L

#### Tool Boxes for Complex Molecules

- · Bispecifics: Optimize plasmids ratio / culture duration / cell culture media, to improve titer and quality, and reduce mismatches
- · Proteins: Tool boxes in clone screening to adjust glycotype and PTMs


#### GenScript ProBio delivers cell lines with superior productivity



40 30 20 10 0 3-4 4-5 5-8 >8

\* The titers before process development Statistics by Dec. 2023

#### GenScript ProBio has vast experiences in cell line development of complex molecules



## Industry-leading Timeline

- 8 weeks from transfection to PCB
- 12 weeks from gene synthesis to PCB

mAb titer distribution 50 Percentage %

# **Cell Line Development for Afucosylated Antibodies**

Antibody-dependent cellular cytotoxicity (ADCC), is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell. It is important in the efficacy of cancer antibodies, but with many approved cancer antibodies there is less ADCC than could be desired due to nonspecific IgG competing with the drugs for binding to FcyIIIa (CD16a) on natural killer cells (NK cells). Afucosylated antibodies overcome this problem through improved FcyIIIa binding.

GenScript ProBio has developed ADCC-enhanced host cell line (CHOK1-ADCC+), which can produce afucosylated antibodies with enhanced ADCC activity.



Proprietary ADCC-enhanced CHO cell line with no IP issue

- In-house developed FUT8 knockout CHO cell line
- · Free to operate

Fast Sample Preparation / Cell Line Development for Different Applications


- Gene synthesis to purified afucosylated antibodies in 4 weeks
- Gene synthesis to top 6 clones in 12 weeks
- · Gene synthesis to top 1 clones in 16 weeks

#### **5** Analytical Methods Available for ADCC Effect Evaluation


- For glycan profiling: LC-MS & HPLC
- For ADCC potency evaluation: affinity measurement to Fcγ Receptor (CD16a), reporter gene assay, PBMC-based assay

## CHOK1-ADCC+ Case Study


CHOK1-ADCC cell line shows great performance in stability




CHOK1-ADCC shows similar performance in productivity as compared to CHOK1-GenS (top 1 clone)



The antibody was successfully afucosylated by using CHOK1-ADCC+ No differences in glycoforms were observed between P0 and P20 samples





## ProBio Cell Line Development Services

We provide 4 stable-expression-based services to meet the different needs in discovery and preclinical development stage.

|                       | ProGram  | PreCLD  | ProCLD                   | ProCLD plus                            |
|-----------------------|--|---|--------------------------|--|
| Service content       | Fast sample preparation                              | Cell pool<br>development  | Cell line<br>development | Cell line development clone evaluation |
| Timeline              | 4 weeks  | 9 weeks   | 12 weeks                 | 16 weeks                               |
| Deliverables          | Target protein, ROA                                  | 4 cell pools  | 6 PCBs                   | Top 1 clone                            |
| Application scenarios | Late discovery stage                                 | Late discovery stage  | Preclinical CMC stage    | Preclinical CMC stage                  |
| Applications          | Determine CMC candidate<br>Developability assessment | Determine CMC candidate<br>Developability assessment<br>Proceed to a stable cell line | IND                      | IND                                    |

## **ProBio Cell Line Platform License**

In addition to cell line development services, we also offer the option of cell line platform license to pharma & biotech customers for regulatory filing and biomanufacturing of human and animal drugs.

The features of our cell line platform license model are summarized as below:

- Lum-sum payment
- Royalty-free
- No clinical & product launch milestone payment
- Incentives for GMP manufacturing in GenScript ProBio

| Platform License Package        |   |  |  |  |
|---------------------------------|---|--|--|--|
| Host system                     | CHOK1-GenS /CHOK1-ADCC+ cell line<br>Proprietary pGenHT 1.0-DGV vector  |  |  |  |
| Full Traceability Documentation | Adaptation report<br>cGMP cell banking report<br>cGMP cell bank testing report<br>Vector synthesis report<br>Vector map and key element description |  |  |  |
| Detailed Protocols and Guidance | Cell line development & cell culture protocol<br>Clone strategy   |  |  |  |

Contact us Website: www.genscriptprobio.com

Tel : +1-732-885-9188 (US) +86-400-025-8686-3172 (CN) Address : Genscript ProBio USA Inc. 20 Kingsbridge Rd,Piscataway, NJ 08854, USA